Home » Topics » Disease categories and therapies » Urology

Urology
RSS

New vasopressin V2 antagonists in development at Wakamoto

April 23, 1998

Synthelabo discloses new benzimidazoles for urinary incontinence

April 21, 1998

Alza acquires Canadian rights to Ditropan

April 20, 1998

Agents for urinary incontinence and IBS in development at Pharmacia & Upjohn

April 17, 1998

New agents for BPH emerge from Synaptic/Merck & Co. collaboration

April 9, 1998

Expanded indication approved for Proscar

April 8, 1998

YM-905 shows promise as safe and effective treatment for overactive detrusor

April 6, 1998

RS-100975, a prostate-selective alpha-blocker in vitro

April 6, 1998

The alpha1L-adrenoceptor: a new target for BPH therapy

April 6, 1998

American Home Products synthesizes and evaluates new smooth muscle relaxants

April 6, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.